Guardant, Nuvalent link diagnostics to targeted cancer pipeline
Bottom line
Guardant Health and Nuvalent have entered a multi-year strategic collaboration to develop companion diagnostics for Nuvalent’s targeted cancer pipeline, using Guardant’s Infinity platform and an initial emphasis on Guardant360 Tissue. Under the deal, Guardant’s tissue and liquid biopsy tests will be used in certain Nuvalent global clinical studies, the companies will evaluate assays that could support future regulatory approvals, and they may work together on commercialization if Nuvalent’s products are approved. The announcement comes as Nuvalent advances late-stage programs in ALK-positive and ROS1-positive non-small cell lung cancer, including an NDA submission for neladalkib in April 2026 and an FDA review for zidesamtinib with a September 18, 2026, PDUFA date. (investors.guardanthealth.com)
Why it matters: While this is a human oncology deal rather than a veterinary one, it’s another signal that biomarker-led drug development and companion diagnostics are becoming more tightly linked across oncology. For veterinary professionals watching the diagnostics market, the partnership underscores how tissue and liquid biopsy platforms are increasingly being positioned not just as testing tools, but as part of the regulatory and commercialization strategy around targeted therapies. It also adds to a pattern for Guardant, which recently highlighted similar pharma collaborations as part of its broader oncology growth story. (fiercebiotech.com)
What to watch: The next milestones are likely to be Nuvalent’s regulatory updates, including the September 18, 2026, FDA action date for zidesamtinib and any future disclosure about which specific Nuvalent programs will get companion diagnostic support under the Guardant deal. (investors.nuvalent.com)
Guardant Health has signed a multi-year strategic collaboration with Nuvalent to develop companion diagnostics and support potential commercialization of Nuvalent’s targeted cancer therapies, extending Guardant’s push to make its Infinity platform part of drug development as well as testing. The companies said the partnership will use Guardant’s tissue and liquid biopsy portfolio in certain Nuvalent global clinical studies, assess companion diagnostic opportunities for Nuvalent’s investigational candidates, and potentially support commercial rollout in major markets if those therapies win approval. (investors.guardanthealth.com)
The timing matters because Nuvalent is moving closer to potential first approvals. The Cambridge, Massachusetts-based biotech is developing precision therapies for kinase-driven cancers, with lead programs in ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer. In recent company updates, Nuvalent said it submitted an NDA for neladalkib in TKI pre-treated advanced ALK-positive NSCLC on April 7, 2026, while zidesamtinib for TKI pre-treated advanced ROS1-positive NSCLC remains under FDA review with a September 18, 2026, PDUFA target action date. (investors.guardanthealth.com)
Guardant’s side of the story is also bigger than a single deal. In its May 7, 2026, first-quarter earnings release, the company called out the Nuvalent collaboration as a recent operating highlight and said the initial emphasis is on Guardant360 Tissue. Guardant also reported first-quarter 2026 revenue of $301.7 million, up 48% year over year, including $205.0 million in oncology revenue and $53.0 million in biopharma and data revenue, suggesting these pharma-linked partnerships sit inside a broader strategy to grow both testing volume and biopharma services. (investors.guardanthealth.com)
Industry coverage framed the agreement as part of a wider pattern. Fierce Biotech noted that the Nuvalent collaboration follows similar Guardant partnerships with Pfizer and Merck, and described the deal as another example of biomarker-driven development becoming more central to oncology R&D and regulatory strategy. That interpretation is consistent with Guardant’s own messaging that precision diagnostics can help identify appropriate patients, improve trial efficiency, and support approvals. (fiercebiotech.com)
There doesn’t appear to be much independent expert commentary yet beyond trade coverage and company statements, and neither company disclosed financial terms. Still, the structure of the collaboration is notable: it spans clinical trial support, companion diagnostic development, and possible post-approval commercialization. That makes it more comprehensive than a simple testing-services agreement, and suggests both companies are planning early for how diagnostic selection could be integrated into eventual market access. This is an inference based on the scope of the announced collaboration and the stage of Nuvalent’s lead programs. (investors.guardanthealth.com)
Why it matters: For veterinary professionals, the direct clinical relevance is limited because the deal is focused on human oncology. But strategically, it’s useful to watch. Companion diagnostics, liquid biopsy, and tissue profiling are increasingly being treated as infrastructure for precision medicine, not add-ons. That matters for veterinary oncology because the same commercial logic, pairing targeted therapies with validated biomarker testing, could shape future expectations around oncology diagnostics in animal health as precision approaches mature. It also reinforces how diagnostics companies are trying to secure value not only from testing, but from drug-development partnerships, regulatory alignment, and downstream commercialization. (investors.guardanthealth.com)
What to watch: Near term, the clearest catalysts are Nuvalent’s regulatory and data milestones, including the September 18, 2026, PDUFA date for zidesamtinib and ASCO data presentations for neladalkib from May 29 to June 2, 2026. Longer term, watch for any indication of which Nuvalent assets will get formal companion diagnostic programs, whether Guardant’s tissue-first approach expands into liquid biopsy CDx work, and whether this deal produces the kind of label-linked diagnostic partnerships that have become more common in human oncology. (investors.nuvalent.com)